Glenmark Gets USFDA Nod For Generic Diabetes Treatment Drug
BENGALURU: Glenmark Pharmaceuticals said it has received the final approval from U.S. health regulator for its generic version of desmopressin acetate tablets used in treatment of diabetes and bed-wetting.
The approval by the U.S. Food and Drug Administration is for strengths of 0.1 mg and 0.2 mg and the company plans to commence shipping the tablets to the US immediately, the pharma company said in a statement.
Desmopressin Acetate is sold under the trademark DDAVP by Ferring Pharmaceuticals. Citing IMS data, Glenmark said, "DDAVP market achieved annual sales of approximately $72.1 million" in the 12 month period.
Glenmark's current portfolio consists of 97 productsauthorised for distribution in the U.S. and 68 abbreviated new drug approvals with the USFDA. Shares of Glenmark Pharmaceuticals were trading at 874.75 per scrip in afternoon trade, up 2.04 per cent from the previous close on the BSE.
High Job Potential Sectors To Be Opened Up For FDI: PM Modi
Renewable Energy Gains Momentum In India: U.S.